Compare Citius Pharmaceuticals Inc (CTXR) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hershey Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Hershey Co trades at $172.1 (market cap $34.78B). The key difference: Hershey Co is far larger — about 2375.7× Citius Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.39% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HSY | |
|---|---|---|
Market Cap | $14.64M | $34.78B |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $236.28 |
52-Week Low | $0.53 | $162.31 |
Enterprise Value | $10.86M | $39.58B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Hershey (HSY) trades at $175.24, up 0.91% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.35 versus $2.04 expected. Revenue growth is steady, with 2025 revenue at $11.69 billion, though net income margin compressed to 9.12% from prior years. Analyst consensus price target is $209.25, implying significant upside, supported by a 3.3% dividend yield and recent margin recovery trends.
The outlook for HSY is cautiously optimistic, with earnings momentum and valuation support offset by near-term technical weakness. Investment opportunity lies in continued execution on margin improvement and innovation, such as new REESE'S PIECES products. Key risks include persistent input cost pressures, competitive threats, and macroeconomic sensitivity. Wall Street sentiment is mixed, with 65.7% hold ratings reflecting balanced risk-reward amid recovery phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
